Skip to main content

Table 3 SSE risk ratio between groups

From: Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Variable

Denosumab (n = 120)

ZA(n = 122)

P - value

Total SSE HR(95%CI)

12.43

19.92

0.002*

 

(2.17-17.44)

(3.34–21.35)

 

SSE HR(95%CI)

within 2 years

6.33

7.27

0.106*

 

(1.36-12.38)

(1.54–19.63)

 

after 2 years

36.26

83.52

0.001*

 

(3.31-161.15)

(4.29–92.60)

 
  1. * Statistically significant values. SSEs: symptomatic skeletal events; ZA: zoledronic acid; HR: hazard ratio; CI: confidence interval
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us